Insulin-like growth factor I receptors are more abundant than insulin receptors in human micro- and macrovascular endothelial cells

American Journal of Physiology - Endocrinology and Metabolism

Volumn 286, Issue 6 49-6, 2004, Pages

  Chisalita, Simona I ^a   Arnqvist, Hans J ^a,b  

^a LINKÖPING UNIVERSITY   (Sweden)

^b LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Glargine; Human endothelial cells; Insulin; Receptor

Indexed keywords

GLUCOSE; INSULIN; INSULIN DERIVATIVE; INSULIN GLARGINE; INSULIN RECEPTOR; RECEPTOR SUBUNIT; SOMATOMEDIN C RECEPTOR; THYMIDINE;

ARTICLE; BINDING AFFINITY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DIABETES MELLITUS; DNA SYNTHESIS; ENDOTHELIUM CELL; GENE EXPRESSION; GLUCOSE METABOLISM; HORMONE RECEPTOR INTERACTION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; MICROANGIOPATHY; MICROVASCULATURE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR DENSITY; VASCULAR DISEASE; VASCULAR ENDOTHELIUM; WESTERN BLOTTING;

AORTA; BLOTTING, WESTERN; ENDOTHELIUM, VASCULAR; GENE EXPRESSION; GLUCOSE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN-LIKE GROWTH FACTOR I; IODINE RADIOISOTOPES; MICROCIRCULATION; PRECIPITIN TESTS; RADIOLIGAND ASSAY; RECEPTOR, IGF TYPE 1; RECEPTOR, INSULIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SKIN; THYMIDINE; TRITIUM;

EID: 2442711785     PISSN: 01931849     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpendo.00327.2003     Document Type: Article

References (45)

1. Aljada A, Ghanim H, Assian E, and Dandona P. Tumor necrosis factor-alpha inhibits insulin-induced increase in endothelial nitric oxide synthase and reduces insulin receptor content and phosphorylation in human aortic endothelial cells. Metabolism 51: 487-491, 2002.
2. Arnqvist HJ, Bornfeldt KE, Chen Y, and Lindstrom T. The insulin-like growth factor system in vascular smooth muscle: interaction with insulin and growth factors. Metabolism 44: 58-66, 1995.
3. Bahr M, Kolter T, Seipke G, and Eckel J. Growth promoting and metabolic activity of the human insulin analogue [GlyA21, ArgB31, ArgB32] insulin (HOE 901) in muscle cells. Eur J Pharmacol 320: 259-265, 1996.
4. Bar RS, Hoak JC, and Peacock ML. Insulin receptors in human endothelial cells: identification and characterization. J Clin Endocrinol Metab 47: 699-702, 1978.
5. Bar RS, Peacock ML, Spanheimer RG, Veenstra R, and Hoak JC. Differential binding of insulin to human arterial and venous endothelial cells in primary culture. Diabetes 29: 991-995, 1980.
6. Bonetti PO, Lerman LO, and Lerman A. Endothelial dysfunction: a marker of atherosclerotic risk. Arterioscler Thromb Vasc Biol 23: 168-175, 2003.
7. Bulow B, Hagmar L, and Eskilsson J. Hypopituitary females have a high incidence of cardiovascular morbidity and an increased prevalence of cardiovascular risk factors. J Clin Endocrinol Metab 85: 574-584, 2000.
8. Ciaraldi TP, Carter L, Seipke G, Mudaliar S, and Henry RR. Effects of the long-acting insulin analog insulin glargine on cultured human skeletal muscle cells: comparisons to insulin and IGF-I. J Clin Endocrinol Metab 86: 5838-5847, 2001.
9. Cines DB, Pollak ES, Buck CA, Loscalzo J, Zimmerman GA, McEver RP, Pober JS, Wick TM, Konkle BA, Schwartz BS, Barnathan ES, McCrae KR, Hug BA, Schmidt AM, and Stern DM. Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood 91: 3527-3561, 1998.
10. Dupont J and Le Roith D. Insulin and insulin-like growth factor I receptors: similarities and differences in signal transduction. Horm Res 55, Suppl 2: 22-26, 2001.
11. Ekman B, Nystrom F, and Arnqvist HJ. Circulating IGF-I concentrations are low and not correlated to glycaemic control in adults with type I diabetes. Ear J Endocrinol 143: 505-510, 2000.
12. Federici M, Menghini R, Mauriello A, Hribal ML, Ferrelli F, Lauro D, Sbraccia P, Spagnoli LG, Sesti G, and Lauro R. Insulin-dependent activation of endothelial nitric oxide synthase is impaired by O-linked glycosylation modification of signaling proteins in human coronary endothelial cells. Circulation 106: 466-472, 2002.
13. Frystyk J, Skjaerbaek C, Dinesen B, and Orskov H. Free insulin-like growth factors (IGF-I and IGF-II) in human serum. FEBS Lett 348: 185-191, 1994.
14. Giannini S, Cresci B, Pala L, Ciucci A, Franchini A, Manuelli C, Fujita-Yamaguchi Y, Cappugi P, Zonefrati R, and Rotella CM. IGFBPs modulate IGF-I- and high glucose-controlled growth of human retinal endothelial cells. J Endocrinol 171: 273-284, 2001.
15. Hanaire-Broutin H, Sallerin-Caute B, Poncet MF, Tauber M, Bastide R, Rosenfeld R, and Tauber JP. Insulin therapy and GH-IGF-I axis disorders in diabetes: impact of glycaemic control and hepatic insulinization. Diabetes Metab 22: 245-250, 1996.
16. Harrela M, Qiao Q, Koistinen R, Tuomilehto J, Nissinen A, Seppala M, and Leinonen P. High serum insulin-like growth factor binding protein-I is associated with increased cardiovascular mortality in elderly men. Horm Metab Res 34: 144-149, 2002.
17. Hovind P, Tarnow L, Rossing K, Rossing P, Eising S, Larsen N, Binder C, and Parving HH. Decreasing incidence of severe diabetic microangiopathy in type 1 diabetes. Diabetes Care 26: 1258-1264, 2003.
18. Jamali R and Arnqvist HJ. IGF-I but not insulin inhibits apoptosis at a low concentration in vascular smooth muscle cells. J Endocrinol 179: 267-274, 2003.
19. Jialal I, Crettaz M, Hachiya HL, Kahn CR, Moses AC, Buzney SM, and King GL. Characterization of the receptors for insulin and the insulin-like growth factors on micro- and macrovascular tissues. Endocrinology 117: 1222-1229, 1985.
20. Juul A, Scheike T, Davidsen M, Gyllenborg J, and Jorgensen T. Low serum insulin-like growth factor I is associated with increased risk of ischemic heart disease: a population-based case-control study. Circulation 106: 939-944, 2002.
21. King GL, Buzney SM, Kahn CR, Hetu N, Buchwald S, Macdonald SG, and Rand LI. Differential responsiveness to insulin of endothelial and support cells from micro- and macrovessels. J Clin Invest 71: 974-979, 1983.
22. King GL, Goodman AD, Buzney S, Moses A, and Kahn CR. Receptors and growth-promoting effects of insulin and insulinlike growth factors on cells from bovine retinal capillaries and aorta. J Clin Invest 75: 1028-1036, 1985.
23. Kurtzhals P, Schaffer L, Sorensen A, Kristensen C, Jonassen I, Schmid C, and Trub T. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 49: 999-1005, 2000.
24. Landin-Wilhelmsen K, Wilhelmsen L, Lappas G, Rosen T, Lindstedt G, Lundberg PA, and Bengtsson BA. Serum insulin-like growth factor I in a random population sample of men and women: relation to age, sex, smoking habits, coffee consumption and physical activity, blood pressure and concentrations of plasma lipids, fibrinogen, parathyroid hormone and osteocalcin. Clin Endocrinol (Oxf) 41: 351-357, 1994.
25. Le Roith D, Bondy C, Yakar S, Liu JL, and Butler A. The somatomedin hypothesis: 2001. Endocr Rev 22: 53-74, 2001.
26. Moxham CP, Duronio V, and Jacobs S. Insulin-like growth factor I receptor beta-subunit heterogeneity. Evidence for hybrid tetramers composed of insulin-like growth factor I and insulin receptor heterodimers. J Biol Chem 264: 13238-13244, 1989.
27. Nilsson J and Thyberg J. Fine structure of arterial smooth muscle cells cultured in the presence of whole blood serum or plasma-derived serum. Cell Tissue Res 223: 87-99, 1982.
28. Nystrom FH, Ohman PK, Ekman BA, Osterlund MK, Karlberg BE, and Arnqvist HJ. Population-based reference values for IGF-I and IGF-binding protein-1: relations with metabolic and anthropometric variables. Eur J Endocrinol 136: 165-172, 1997.
29. Ohashi H, Rosen KM, Smith FE, Villa-Komaroff L, Nayak RC, and King GL. Characterization of type I IGF receptor and IGF-I mRNA expression in cultured human and bovine glomerular cells. Regul Pept 4: 9-20, 1993.
30. Pandini G, Frasca F, Mineo R, Sciacca L, Vigneri R, and Belfiore A. Insulin/insulin-like growth factor I hybrid receptors have different biological characteristics depending on the insulin receptor isoform involved. J Biol Chem 277: 39684-39695, 2002.
31. Rechler MM and Nissley SP. The nature and regulation of the receptors for insulin-like growth factors. Annu Rev Physiol 47: 425-442, 1985.
32. Rosen OM. After insulin binds. Science 237: 1452-1458, 1987.
33. Rosen T and Bengtsson BA. Premature mortality due to cardiovascular disease in hypopituitarism. Lancet 336: 285-288B, 1990.
34. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 362: 801-809, 1993.
35. Rossetti P, Pampanelli S, Fanelli C, Porcellati F, Costa E, Torlone E, Scionti L, and Bolli GB. Intensive replacement of basal insulin in patients with type 1 diabetes given rapid-acting insulin analog at mealtime: a 3-mo comparison between administration of NPH insulin four times daily and glargine insulin at dinner or bedtime. Diabetes Care 26: 1490-1496, 2003.
36. Saltiel AR and Kahn CR. Insulin signalling and the regulation of glucose and lipid metabolism. Nature 13: 799-806, 2001.
37. Shimasaki S and Ling N. Identification and molecular characterization of insulin-like growth factor binding proteins (IGFBP-1, -2, -3, -4, -5 and -6). Prog Growth Factor Res 3: 243-66, 1991.
38. Soos MA, Field CE, and Siddle K. Purified hybrid insulin/insulin-like growth factor-I receptors bind insulin-like growth factor-I, but not insulin, with high affinity. Biochem J 290: 419-426, 1993.
39. Spoerri PE, Ellis EA, Tarnuzzer RW, and Grant MB. Insulin-like growth factor: receptor and binding proteins in human retinal endothelial cell cultures of diabetic and non-diabetic origin. Growth Horm IGF Res 8: 125-132, 1998.
40. Stehouwer CD, Lambert J, Donker AJ, and van Hinsbergh VW. Endothelial dysfunction and pathogenesis of diabetic angiopathy. Cardiovasc Res 34: 55-68, 1997.
41. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 12: 837-853, 1998.
42. Ullrich A, Bell JR, Chen EY, Herrera R, Petruzzelli LM, Dull TJ, Gray A, Coussens L, Liao Y, and Tsubokawa M. Human insulin receptor and its relationship to the tyrosine kinase family of oncogenes. Nature 313: 756-761, 1985.
43. Ullrich A, Gray A, Tam AW, Yang-Feng T, Tsubokawa M, Collins C, Henzel W, Le-Bon T, Kathuria S, and Chen E. Insulin-like growth factor I receptor primary structure: comparison with insulin receptor suggests structural determinants that define functional specificity. EMBO J 5: 2503-2512, 1986.
44. Zeng G, Nystrom F, Ravichandran LV, Cong LN, Kirby MBS, Mostowski HBS, and Quon MJ. Roles for insulin receptor, PI3-kinase, and Akt in insulin-signaling pathways related to production of nitric oxide in human vascular endothelial cells. Circulation 101: 1539-1545, 2000.
45. Zeng G and Quon MJ. Insulin-stimulated production of nitric oxide is inhibited by wortmannin, direct measurement in vascular endothelial cells. J Clin Invest 98: 894-898, 1996.